AgomAb Therapeutics NV (AGMB) stock, explained like you're 5

Is AgomAb Therapeutics NV a small, medium or large cap company?

No. AgomAb Therapeutics NV is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 447 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How AgomAb Therapeutics NV makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves AGMB stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• No approved treatment targets Crohn's related bowel scarring. An experimental drug study has begun. (Stock Titan)
• AgomAb Therapeutics NV (AGMB) Stock forecasts (Yahoo Finance Australia)
• The first patient is dosed as AgomAb (AGMB) triggers a payment to former Origo shareholders. (Stock Titan)
• Agomab Drug Shows Sustained Disease Control in Crohn’s Trial AgomAb Therapeutics (NASDAQ:AGMB) (Benzinga)
• AgomAb Therapeutics: High Risk, High Reward Stock (NASDAQ:AGMB) (Seeking Alpha)

Key terms to know before you follow AGMB

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility